Clinical TrialsAcumen's ALTITUDE-AD Phase 2 trial for sabirnetug targets a significant dementia patient segment, with a reliable primary endpoint measure, iADRS score, to capture clinical progression effectively.
Drug EfficacySabirnetug's potential efficacy is supported by promising CSF biomarker data, indicating the drug's impact on disease-modifying biomarkers and its unique approach to treating Alzheimer's.
Regulatory MilestoneWith regulatory feedback from the EMA, the ALTITUDE-AD Study is poised to potentially become a first registrational study, highlighting Acumen's strategic progress in the Alzheimer's disease treatment landscape.